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Salicylurate (SU) is the major metabolite in urine of acetylsalicylic acid (aspirin) and can be used as a metric to monitor
aspirin pharmacokinetics and as an indicator of appendicitis, anemia, and liver disease. Detection in urine and plasma
currently requires solvent extraction or other sample handling prior to analysis. We present a simple method to quantify
SU in urine via chelation to a terbium binary complex with the macrocycle 1,4,7,10-tetraazacyclododecane-1,7-
bisacetate (DO2A). Binding of SU to form the [Tb(DO2A)(SU)]- ternary complex triggers intense luminescence under
UV excitation due to an absorbance-energy transfer-emission mechanism. Here we report characterization of the
[Tb(DO2A)(SU)]- ternary complex and application of this sensitized lanthanide luminescence method to quantify SU
in urine samples following a low-dose aspirin regimen.
Introduction
Acetylsalicylic acid (ASA), commonly known as aspirin, is
one of themostwidely used therapeutic substances.Aspirin is
effective as an antiinflammatory agent, an analgesic to relieve
minor aches and pains, and an antipyretic to reduce fever.1 It
is also the primary medication used to treat chronic rheu-
matic fever, rheumatoid arthritis, and osteoarthritis.2 Further,
recent studies have shown the antithrombotic benefits of an
aspirin regimen in stroke prevention.3,4 The widespread use
of aspirin mandates a complete and thorough understanding
of the pharmacodynamics and pharmacokinetics of this
medication in the human body. In addition, salicylates are
used as markers to assess free-radical damage in vivo due to
hydroxyl radicals.5 As a result, a detection method to moni-
tor acetylsalicylate and its metabolites in blood plasma and
urine;with high sensitivity at low cost;is in high demand.
In the body, ASA is hydrolyzed to salicylic acid (SA) by
carboxylesterases in the gut walls and liver, with an elimination
half-life of 15-20 min.6 SA is then metabolically converted
primarily to salicyluric acid (SU) and other metabolites,
which are excreted in the urine.7,8 Because of the high
elimination rate constant for SU in comparison to SA9 and
the fact that endogenous SU formation only occurs in a
limited capacity,10,11 it is possible to use SUurinary excretion
data to establish a relationship between SU formation and
the amount of SA in the body.We can therefore use SU as an
indicator of SA in vivo, and hence detection of SU in urine
can be utilized as a noninvasive means of monitoring aspirin
dosage and residence in the body. Further, unusually high or
low concentrations of SU in urine have been correlated to
a variety of diseases and conditions, such as appendicitis,
anemia, abdominal trauma, liver diseases, uremia, andDown’s
Syndrome.12 Hence, detection of SU in urine has a variety of
applications, including a facile way tomonitor aspirin dosage
and corroborate the presence of certain medical conditions.
Current detection methods of salicylates in blood and
urine involve significant sample preparation prior to analysis
and are time- and/or labor-intensive.High-performance liquid
chromatography (HPLC) can be used to detect ASA, SA,
and SU simultaneously with a sensitivity of 0.1 mg/L,13 but
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this requires solvent extraction and the addition of internal
standards. Other HPLC techniques report sensitivities of
0.2 mg/L of SA in urine7 and 0.5 mg/L of SA in plasma.14
A liquid chromatographic method with UV detection has a
sensitivity of 0.5 mg/L with a precision of 8.6 mg/L but takes
25 min and requires purification steps.15 Capillary electro-
phoresis coupled to laser-induced fluorescence has also been
described to detect SA, SU, and other metabolites in urine
following sample filtration and dilution.16 A spectrophoto-
metricmethodusing absorption spectra andmulticomponent
analysis can distinguish between SA and SU but not in blood
or urine.17 We therefore seek a method with similar sensiti-
vity, but with greater efficiency and reduced cost.
Salicylurate has been shown to bind metal cations such as
divalent copper,18 trivalent cobalt,19 VOIV,20 and dimethyl-
tin(IV).21 In such complexes, SU is either bidentate or tri-
dentate, coordinating through the carbonyl, carboxyl and
phenolate oxygen atoms of the ligand. Lanthanides are hard
ions andmake excellent chelators for oxygen-containing ligands.
However, no lanthanide complexes containing ligated SU have
been reported in the literature. Europium-macrocycle com-
plexes have previously been applied to the detection of analytes
in urine such as lactate and citrate.22,23 Here, we report the first
lanthanide/macrocycle receptor to detect salicylurate in urine.
We have selected the [Tb(DO2A)]þ binary complex, where
DO2A is the macrocyclic ligand 1,4,7,10-tetraazacyclodode-
cane-1,7-bisacetate, as our first-generation salicylurate recep-
tor site. Terbium is the only luminescent lanthanide with a
single excited state (5D4, 20500 cm
-1)24 lying below the
triplet excited state of salicylate (23 000 cm-1)25 that is
responsible for sensitization via energy transfer to the lantha-
nide.26 Europium, dysprosium, and samarium all have at
least two excited-state energy levels below the chromophore
triplet, which results inmultiple nonradiative deactivation path-
ways and decreased luminescence intensity.27-29 Terbium
also has a large energy gap between the lowest-lying excited
state and the 7Fn ground-state manifold, allowing for intense
emission in the visible region (λmax=544 nm).
24 The DO2A
ligand binds Tb3þ with high affinity (log KGdDO2A=19.4
30),
conferring thermodynamic stability and reducing vibrational
quenching of luminescence by excluding solvent molecules
fromthe lanthanide coordination sphere.We therefore expected
coordination of the salicylurate analyte to produce a strongly
luminescent [Tb(DO2A)(SU)]- ternary complex. This work
demonstrates a proof-of-concept in terms of designing a
lanthanide-based receptor site to monitor medication dosage
in a manner that is rapid and cost-effective.
Experimental Section
Materials. The following chemicals were purchased and used
as received: ammonium hydroxide (28-30% NH4OH in water;
Mallinckrodt Baker, Phillipsburg, NJ), N-cyclohexyl-3-amino-
propanesulfonic acid (CAPS) buffer (Alfa Aesar, Lancashire,
U.K.), N-cyclohexyl-2-aminoethanesulfonic acid (CHES) buffer
(Alfa Aesar), 2-(N-morpholino)ethanesulfonic acid monohyd-
rate (MES monohydrate) buffer (Alfa Aesar), sodium acetate
trihydrate (Mallinckrodt), sodiumhydroxide (50%NaOHinwater)
(Mallinckrodt), N-tris(hydroxymethyl)methyl-3-aminopropane-
sulfonic acid (TAPS) buffer (TCI America, Portland, OR),
terbium(III) chloride hexahydrate (Alfa Aesar), and SU
(salicyluric acid, 2-hydroxyhippuric acid; Acros Organics, Geel,
Belgium). The TbCl3 salt was 99% pure, all buffers were at least
98% pure, and SU was 97% pure. Water was deionized to a
resistivity of 18.2 MΩ 3 cm using a Purelab Ultra laboratory water
purification system (Siemens Water Technologies, Warrendale,
PA). The 1,4,7,10-tetraazacyclododecane-1,7-diacetate (DO2A)
ligand was prepared by hydrolysis of 1,4,7,10-tetraazacyclodo-
decane-1,7-di-tert-butyl acetate (Macrocyclics, Dallas, TX), as
described previously,31 resulting in a white solid in 79.9% yield.
DO2A 3 0.6H2O 3 2.1HCl. Anal. Calcd (found) for C12H24N4O4 3
2.80HCl 3 0.85H2O (fw=378.18): C, 38.32 (38.32); H, 7.31 (7.19);
N, 14.89 (14.54); Cl, 20.0 (20.0).
The [Tb(DO2A)(SU)]- ternary complex was prepared in aqu-
eous solution by the addition of 0.464 mL of 0.032318 M TbCl3
(15.00 μmol) to 0.269 mL of 0.5593 M DO2A (15.05 μmol),
followed by 1.650 mL of 9.0717 mM SU (14.97 μmol). The pH
was adjusted to 8.0withammoniumhydroxide (28-30%inwater),
addeddropwise. TOF-MSES-. Calcd (found) for TbC21H29N5O8
(M-): m/z 638.41 (m/z 638.13).
Methods. All samples were prepared in triplicate to a final
volume of 3.50 mL in disposable acrylate cuvettes (Spectrocell,
Oreland, PA) with a 1 cm path length. Luminescence spectral
analysis was performed by a Fluorolog-3 fluorescence spectro-
meter (model FL3-22, Horiba Jobin-Yvon, Edison, NJ). To
prevent second-order diffraction of the source radiation, all
measurements were taken with a 350 nm colorless sharp cut-
off glass filter (03 FCG 055, Melles Griot, Covina, CA). All
reported spectra were obtained as a ratio of corrected signal to
corrected reference (Sc/Rc) to eliminate the effect of varying the
background radiation in the sample chamber; emission inten-
sities are in units of counts per second per microampere (cps/μA).
Integrated intensities are evaluated over 534-554 nm, except as
noted. Error bars are set at 1 standard deviation from the mean.
Spectroscopy. Luminescence excitation (λex = 316 nm) and
emission (λem = 544 nm) spectra were obtained for the [Tb-
(DO2A)(SU)]- ternary complex, 100 μM in 0.1 M TAPS
buffer, pH 8.4. Absorption spectra were obtained using a Cary
50 Bio UV/visible spectrophotometer (Varian, Inc., Palo Alto,
CA) in quartz cuvettes. Because of SU intrinsic luminescence, all
integration values are reported after emission spectra are fit and
then subtracted to a SU aqueous solution to isolate the bound
Tb/SU signal.
Binding Stoichiometry. A method of continuous variations
was used to determine the binding stoichiometry for the
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Tb/DO2A/SU system. Samples were prepared in 0.1 M TAPS
buffer (pH 8.4), with the concentrations of Tb and SU varying
inversely from 0 to 120 μM in 10 μM increments and the con-
centration of DO2A maintained at 500 μM. Emission spectra
were obtained following 1-3 h of equilibration time.
pHDependence Study. Solutions of 100 μM [Tb(DO2A)(SU)]-
were prepared in 0.1 M buffer with 5-fold excess DO2A to ensure
full Tb complexation. Four buffers were used: MES (pKa=6.1),
TAPS (pKa=8.4), CHES (pKa=9.3), and CAPS (pKa=10.4),
with pH adjustment to within 0.1 of the pKa value using 50%
NaOH, added dropwise. Sodium acetate trihydrate, 0.2 M, was
also used to maintain a pH of 7.5. Emission spectra were obtained
after 15 min, 18 h, and 5 days.
Calibration Curve and Limit of Detection (LOD). Urine was
collected from healthy volunteers, with unmarked samples chosen
at random from a larger sample set for analysis within 24 h of
donation. Samples, kept refrigerated until use, were spiked with
SU over a range from 0 to 150 μM.An aliquot from each spiked
sample was diluted into a preequilibrated solution containing
5 mM [Tb(DO2A)]þ in a 0.1MTAPS buffer (pH 8.4) in various
volumes, and the emission spectra were obtained within 1 h of
dilution. Intrinsic SU fluorescence was eliminated from the
emission spectra using a fitting algorithm, and the largest ter-
bium emission peak at 544 nmwas integrated and normalized to
an external standard. A linear regression model was used to
determine the endogenous SU concentration in each donated
sample by setting the y intercept to the integrated intensity of
5 mM [Tb(DO2A)]þ alone (I0) and solving for an endogenous
SU concentration [SU]end such that the correlation coefficient
(R2) is optimized to near unity.
Iobs ¼ Cð½SUspike þ ½SUendÞ þ I0
In this model, Iobs is the observed integrated intensity of the
spiked sample in 5 mM [Tb(DO2A)]þ, [SU]spike is the concen-
tration of SU added to the sample, and C is the calibration
constant, in units of cps/M 3 μA. It was empirically determined
from these experiments that a sample dilution factor of 1:350
produces a linear, reproducible correlation between the SU
concentration and emission intensity (C) that is independent
of the donor. A calibration curve was generated from this data
set and can be applied to any urine sample to determine the SU
concentration.
The LOD for SU in urine was identified for a signal-to-noise
ratio of 3:1. An average noise value was obtained from an emis-
sion spectrum used in the calibration curve (λem=544 nm); this
was multiplied by the S/N ratio and added to the background
intensity (λem= 542 nm) for a 5 mM Tb(DO2A)
þ control
solution. Integration of the [Tb(DO2A)(SU)]- emission spec-
trum adjusted to this value resulted in an SU concentration
obtained from the constructed calibration curve that corres-
ponds to the LOD for this assay.
Aspirin Study. Samples were collected from a healthy anony-
mous volunteer prior to and following two self-medicated aspirin
regimens. The subject took 81 mg of aspirin every 6 h for a total
of 24 h and provided a urine sample 4 h after the final dose. The
process was repeated again with a 325 mg regimen. Both regi-
mens were within recommended low-dose ranges for stroke and
myocardial infarction prevention.3 A 10 μLaliquot of each sam-
plewas diluted by 1:350 intopreequilibrated 5.0mM[Tb(DO2A)]þ
in 0.1 M TAPS (pH 8.4). Emission spectra (λex=316 nm) were
obtained following 1 min of thorough mixing.
Results and Discussion
The excitation spectrum shows a broad band at 316 nm,
attributed to theπfπ* transition of the SU chromophore.32
The emission spectrum presents a large, broad band with
λmax of 419 nm, presumably because of excited-state intra-
molecular proton transfer (ESIPT) from the hydroxylmoiety
to the nearby carbonyl group of the SU ligand. This type of
ESIPT is known to occur in SA and p-methoxy-substituted
salicylates,with similar excitation and emissionwavelengths.33,34
The unusually large Stokes’ shifts in these compounds are
due to a significant geometry change as the proton-transfer
tautomer is formed and then relaxes to a relatively unstable
isomer of the ground state.35-37 This band at 419 nm can be
used as an internal standard to validate the SU concentration
in solution (see the Supporting Information). The sharp bands
at 488, 545, 585, and 621 nm are the 5D4f
7Fn transitions for
sensitized terbium emission, where n = 6, 5, 4, and 3,
respectively (Figure 1). The intensities of these transitions are
consistent with the luminescence turn-on associated with an
aromatic anion binding to the terbium cation, where efficient
energy transfer to the lanthanide is achieved via the absorption-
energy transfer-emission (AETE) mechanism following UV
excitation and intersystem crossing. This effect results in an
increase in terbium luminescence by three orders of magnitude
ormore and cannot be accounted for simply by the exclusion of
water, which quenches luminescence via nonradiative decay
pathways, from theTb3þ coordination sphere.38,39Amethodof
continuous variations indicates an optimal binding stoichiom-
etryof about 1:1 forTbandSUwithDO2Ainexcess (Figure 2).
We can therefore conclude that SU2- binds to Tb(DO2A)þ to
form the [Tb(DO2A)(SU)]- ternary complex.
To optimize conditions for the detection of SU in complex
matrices, a pHdependence studywas performed frompH6.1
to 10.6. Results indicate that the [Tb(DO2A)(SU)]- complex
Figure 1. Excitation (dashed) and emission (solid) spectra of the [Tb-
(DO2A)(SU)]- complex, 100 μM in a 0.1 M TAPS buffer, pH 8.4 (λex=
316 nm; λem=544 nm).
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is most stable in neutral to slightly basic conditions, with pH
8.4 optimal (see the Supporting Information). This is con-
sistent with the pKa values reported for SU (3.34 and 7.91),
18
suggesting that the SU ligand must be fully deprotonated for
effective terbium binding and efficient energy transfer. Experi-
ments indicate that the [Tb(DO2A)(SU)]- complex is un-
stable after 24 h, as evidenced by a significant loss of signal.
Reproducibility is conserved if samples are analyzed within
6 h of solution preparation.
To determine the efficacy of SU detection using the [Tb-
(DO2A)]þ receptor site in body fluids, urine samples pro-
vided by healthy donors were used to generate a calibration
curve and calculate a LOD. Signal quenching was observed
with high concentrations of urine, probably due to competi-
tion with other ions or loss of the emission signal due to the
high absorptivity of the samples. Dilution of the samplewhile
maintaining a high concentration of [Tb(DO2A)]þ (4-
5 mM) eliminated this problem and produced results similar
to those obtained in aqueous solution (Figure 3). A dilution
factor of 1:350 allows for reproducibility over the entire
sample set tested. Using this dilution factor, a calibration
curve was constructed using spiked SU urine samples from
three separate donors, with a correlation coefficient near
unity (Figure 4). Assuming a signal-to-noise ratio of 3:1, a
LOD for this assay was determined to be 0.027 μMSU in the
diluted samples, which corresponds to an SU concentration
of 9.4 μM in urine or approximately 1.8 mg/L. For a first
iteration of an SU receptor site, this value is already in the
range of highly specialized detection methods such as HPLC
or capillary electrophoresis and can be performed in a frac-
tion of the time.
As a proof-of-concept, we obtained urine samples from a
healthy anonymous volunteer on a low-dose aspirin regimen.
We successfully detected an increase in the luminescence
intensity that tracked with the two aspirin dosage aliquots
of 81 or 325 mg, indicating an increase in SU elimination in
the urine (Figure 5). The intensity of the intrinsic SU
luminescence band (419 nm) is much lower relative to the
terbium emission peaks for this experiment. We attribute the
decrease to absorption and/or quenching by other species in
solution in this region. The unpredictable change in the inten-
sity of this band, which varies significantly between donors,
emphasizes the problems associated with using SU lumine-
scence alone for concentration determination.
We have demonstrated a first-generation SU receptor site
composed of a lanthanide reporter chelated to a selective
macrocyclic ligand. Preliminary results suggest a high degree
of selectivity for SU, even in a matrix as complex as urine.
Complete sample preparation and analysis can be performed
within 5 min. This SU detection assay represents a proof-of-
concept for the design and implementation of lanthanide/
macrocycle receptor sites with high sensitivity and selectivity
for a target biomolecule. Further optimization of the macro-
cycle by adding or substituting functional groups to modify
the electrostatics and sterics of the Tb receptor site should
enhance SUbinding and improve the LODby at least 1 order
Figure 2. Method of continuous variations to determine the binding
stoichiometry of SU to [Tb(DO2A)]þ. [Tb] and [SU] varied inversely from
0 to 120 μM in 10 μM increments with 500 μMDO2A in a 0.1 M TAPS
buffer, pH 8.4 (λex = 316 nm).
Figure 3. Dilution study of an SU-spiked urine sample for dilution fac-
tors of 1:3.5 (dotted), 1:7 (dashed-dotted), and 1:35 (dashed) into 5 mM
[Tb(DO2A)]þ in a 0.1 M TAPS buffer, pH 8.4 (λex = 316 nm). As the
dilution factor is increased, the slope (m) approaches unity, equivalent to
an aqueous solution spiked with SU (solid).
Figure 4. Calibration curve of SU spiked into urine samples (dilution
factor 1:350) from three individual healthy donors, relating the lumine-
scence intensity to the SU concentration. Samples were diluted into 5mM
[Tb(DO2A)]þ in a 0.1 M TAPS buffer, pH 8.4 (λex = 316 nm).
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of magnitude.40 Such an improvement would make this type
of SU detection more sensitive than all other reported tech-
niques, in addition to being more rapid and cost-effective.
Spectroscopic determination of salicylurate by terbium/
macrocycle complexeshas three advantages: (1) rapiddetection
and quantification, (2) low cost, and (3) capability of auto-
mation. We anticipate application of such a straightforward
method for in-line monitoring of SU, possibly via an auto-
mated catheterized system. Salicylurate levels in the blood-
stream could also be determined using sufficiently selec-
tive terbium complexes, though further experimentation is
required.
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Figure 5. Aspirin study showing an increase in luminescence due to
increased ASA dosage (mg). Samples were diluted 1:350 into 5 mM
[Tb(DO2A)]þ in a 0.1 M TAPS buffer, pH 8.4 (λex = 316 nm). Emission
spectra, taken for three separate samples, are nearly superimposable for
each aspirin dosage.
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